Grifols reported EUR979.78M in Cash and Equivalent for its fiscal quarter ending in December of 2024.





Cash And Equivalent Change Date
Alaunos Therapeutics USD 354K 1.03M Mar/2026
Arca Biopharma USD 268.47M 218.95M Jun/2026
aTyr Pharma USD 16.16M 6.15M Jun/2026
Bio Path 13.65M 3.37M Sep/2022
Brainstorm Cell Therapeutics USD 22K 7K Jun/2026
Capricor Therapeutics USD 20.94M 84.49M Jun/2026
Cara Therapeutics USD 19.85M 883K Mar/2026
GlaxoSmithKline GBP 3.44B 292M Mar/2026
Grifols EUR 979.78M 334.84M Dec/2024
Immunic USD 186.63M 171.15M Mar/2026
Minerva Neurosciences USD 82.3M 70.02M Dec/2025
Nektar Therapeutics USD 149.58M 134.46M Mar/2026
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
TherapeuticsMD 523K 89K Jun/2024